南模生物
(688265)
| 流通市值：13.45亿 | | | 总市值：21.23亿 |
| 流通股本：4938.85万 | | | 总股本：7796.35万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 82,932,302.56 | 366,548,781.43 | 267,990,100.5 | 180,775,257.15 |
| 营业收入 | 82,932,302.56 | 366,548,781.43 | 267,990,100.5 | 180,775,257.15 |
| 二、营业总成本 | 99,746,760.11 | 406,101,295.12 | 295,805,196.53 | 192,754,449.08 |
| 营业成本 | 47,016,354.86 | 211,213,022.24 | 154,411,901.65 | 101,696,446.45 |
| 税金及附加 | 880,145.12 | 3,605,268.65 | 1,907,061.77 | 1,117,605.52 |
| 销售费用 | 13,859,227.46 | 51,094,363.52 | 39,427,556.29 | 24,837,511.82 |
| 管理费用 | 17,741,390.5 | 56,422,408.73 | 40,345,010.48 | 25,325,700.97 |
| 研发费用 | 19,334,427.95 | 80,237,407.26 | 58,347,615.01 | 39,267,376.81 |
| 财务费用 | 915,214.22 | 3,528,824.72 | 1,366,051.33 | 509,807.51 |
| 其中:利息费用 | 1,076,862.39 | 5,043,355.14 | 3,850,050.84 | - |
| 其中:利息收入 | -189,189.49 | 2,274,074.16 | 1,942,347.39 | - |
| 加:公允价值变动收益 | 4,764,766.15 | 759,830.85 | 2,085,618.72 | 1,889,742.56 |
| 加:投资收益 | 714,176.57 | 17,250,059.99 | 12,390,230.83 | 7,040,090.58 |
| 资产处置收益 | -7,835.19 | -10,923.26 | -10,923.26 | -10,923.26 |
| 资产减值损失(新) | -1,902,680 | -2,559,865.72 | -2,901,976.92 | -1,788,752.11 |
| 信用减值损失(新) | -880,296.27 | -9,994,761.71 | -5,081,490.95 | -3,213,094.13 |
| 其他收益 | 1,127,723.48 | 4,306,971.07 | 2,113,987.65 | 1,502,781.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -12,998,602.81 | -29,801,202.47 | -19,219,649.96 | -6,559,346.83 |
| 加:营业外收入 | 45,912.99 | 17,303.73 | 3.73 | 3.73 |
| 减:营业外支出 | 32,103.88 | 119,680.18 | 36,995.72 | 27,229.77 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -12,984,793.7 | -29,903,578.92 | -19,256,641.95 | -6,586,572.87 |
| 减:所得税费用 | -87,733 | -9,320,971.87 | -4,644,898.12 | -3,682,875.4 |
| 六、净利润 | -12,897,060.7 | -20,582,607.05 | -14,611,743.83 | -2,903,697.47 |
| 持续经营净利润 | -12,897,060.7 | -20,582,607.05 | -14,611,743.83 | -2,903,697.47 |
| 归属于母公司股东的净利润 | -12,897,060.7 | -20,582,607.05 | -14,611,743.83 | -2,903,697.47 |
| (一)基本每股收益 | -0.17 | -0.26 | -0.19 | -0.04 |
| (二)稀释每股收益 | -0.17 | -0.26 | -0.19 | -0.04 |
| 八、其他综合收益 | -91,122.93 | 184,620.33 | 810,853.08 | 747,854.93 |
| 归属于母公司股东的其他综合收益 | -91,122.93 | 184,620.33 | 810,853.08 | 747,854.93 |
| 九、综合收益总额 | -12,988,183.63 | -20,397,986.72 | -13,800,890.75 | -2,155,842.54 |
| 归属于母公司股东的综合收益总额 | -12,988,183.63 | -20,397,986.72 | -13,800,890.75 | -2,155,842.54 |
| 公告日期 | 2024-04-30 | 2024-04-30 | 2023-10-31 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |